At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Targeting of the Small Airways in Patients With COPD: Airway Effects of Tiotropium - Respimat vs Handihaler
In Brief
A Phase 3 clinical trial evaluating Handihaler-Tiotropium 18 mcg untrained, Handihaler-Tiotropium 18 mcg trained, and 1 other intervention for COPD and LUNG DISEASES, OBSTRUCTIVE. Completed, enrolled 44 participants across 1 site.
Detailed Summary
The aim of the study is to investigate the effect of tiotropium from different devices on a panel of small (IOS, MBNW, DLCO, FVC) and large airway (FEV1, PEF) responses in patients with mild-moderate COPD. Comparisons will be made between Tiotropium Handihaler 18 micrograms once daily and Tiotropium Respimat 5 micrograms once daily
Study Details
Timeline
Interventions
We are looking at the untrained used of Handihaler
We are looking at the trained use of Handihaler after 14 days treatment
we are looking at the trained use of Respimat after 14 days treatment